

Global Opioid-Induced Constipation Market Growth 2025-2031

<https://marketpublishers.com/r/G575CB7820FEN.html>

Date: January 2025

Pages: 114

Price: US\$ 3,660.00 (Single User License)

ID: G575CB7820FEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

The global Opioid-Induced Constipation market size is predicted to grow from US\$ 2707 million in 2025 to US\$ 3581 million in 2031; it is expected to grow at a CAGR of 4.8% from 2025 to 2031.

Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.

Global Opioid-Induced Constipation key players include Sanofi, Bayer, Purdue Pharm, etc. Global top three manufacturers hold a share over 45%.

North America is the largest market, with a share about 55%, followed by Europe, and Asia-Pacific, both have a share about 35 percent.

In terms of product, Lubiprostone is the largest segment, with a share about 5%. And in terms of application, the largest application is Pharmacy, followed by Hospital, etc.

LP Information, Inc. (LPI) ' newest research report, the "Opioid-Induced Constipation Industry Forecast" looks at past sales and reviews total world Opioid-Induced Constipation sales in 2024, providing a comprehensive analysis by region and market sector of projected Opioid-Induced Constipation sales for 2025 through 2031. With Opioid-Induced Constipation sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Opioid-Induced Constipation industry.

This Insight Report provides a comprehensive analysis of the global Opioid-Induced Constipation landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Opioid-Induced Constipation portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Opioid-Induced Constipation market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Opioid-Induced Constipation and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Opioid-Induced Constipation.

This report presents a comprehensive overview, market shares, and growth opportunities of Opioid-Induced Constipation market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Methylnaltrexone Bromide

Lubiprostone

Naloxegol

Others

Segmentation by Application:

Hospital

Pharmacy

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Takeda Pharmaceuticals

Bayer

Sanofi

Mallinckrodt

Salix (Bausch Health)

AstraZeneca

Progenics Pharmaceuticals

Purdue Pharm

Nektar Therapeutics

Daichi Sankyo

Prestige

GSK

Shionogi

Key Questions Addressed in this Report

What is the 10-year outlook for the global Opioid-Induced Constipation market?

What factors are driving Opioid-Induced Constipation market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Opioid-Induced Constipation market opportunities vary by end market size?

How does Opioid-Induced Constipation break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Opioid-Induced Constipation Annual Sales 2020-2031
 - 2.1.2 World Current & Future Analysis for Opioid-Induced Constipation by Geographic Region, 2020, 2024 & 2031
 - 2.1.3 World Current & Future Analysis for Opioid-Induced Constipation by Country/Region, 2020, 2024 & 2031
- 2.2 Opioid-Induced Constipation Segment by Type
 - 2.2.1 Methylnaltrexone Bromide
 - 2.2.2 Lubiprostone
 - 2.2.3 Naloxegol
 - 2.2.4 Others
- 2.3 Opioid-Induced Constipation Sales by Type
 - 2.3.1 Global Opioid-Induced Constipation Sales Market Share by Type (2020-2025)
 - 2.3.2 Global Opioid-Induced Constipation Revenue and Market Share by Type (2020-2025)
 - 2.3.3 Global Opioid-Induced Constipation Sale Price by Type (2020-2025)
- 2.4 Opioid-Induced Constipation Segment by Application
 - 2.4.1 Hospital
 - 2.4.2 Pharmacy
 - 2.4.3 Other
- 2.5 Opioid-Induced Constipation Sales by Application
 - 2.5.1 Global Opioid-Induced Constipation Sale Market Share by Application (2020-2025)
 - 2.5.2 Global Opioid-Induced Constipation Revenue and Market Share by Application

(2020-2025)

2.5.3 Global Opioid-Induced Constipation Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Opioid-Induced Constipation Breakdown Data by Company

3.1.1 Global Opioid-Induced Constipation Annual Sales by Company (2020-2025)

3.1.2 Global Opioid-Induced Constipation Sales Market Share by Company

(2020-2025)

3.2 Global Opioid-Induced Constipation Annual Revenue by Company (2020-2025)

3.2.1 Global Opioid-Induced Constipation Revenue by Company (2020-2025)

3.2.2 Global Opioid-Induced Constipation Revenue Market Share by Company

(2020-2025)

3.3 Global Opioid-Induced Constipation Sale Price by Company

3.4 Key Manufacturers Opioid-Induced Constipation Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Opioid-Induced Constipation Product Location Distribution

3.4.2 Players Opioid-Induced Constipation Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR OPIOID-INDUCED CONSTIPATION BY GEOGRAPHIC REGION

4.1 World Historic Opioid-Induced Constipation Market Size by Geographic Region (2020-2025)

4.1.1 Global Opioid-Induced Constipation Annual Sales by Geographic Region

(2020-2025)

4.1.2 Global Opioid-Induced Constipation Annual Revenue by Geographic Region

(2020-2025)

4.2 World Historic Opioid-Induced Constipation Market Size by Country/Region (2020-2025)

4.2.1 Global Opioid-Induced Constipation Annual Sales by Country/Region

(2020-2025)

4.2.2 Global Opioid-Induced Constipation Annual Revenue by Country/Region

(2020-2025)

- 4.3 Americas Opioid-Induced Constipation Sales Growth
- 4.4 APAC Opioid-Induced Constipation Sales Growth
- 4.5 Europe Opioid-Induced Constipation Sales Growth
- 4.6 Middle East & Africa Opioid-Induced Constipation Sales Growth

5 AMERICAS

- 5.1 Americas Opioid-Induced Constipation Sales by Country
 - 5.1.1 Americas Opioid-Induced Constipation Sales by Country (2020-2025)
 - 5.1.2 Americas Opioid-Induced Constipation Revenue by Country (2020-2025)
- 5.2 Americas Opioid-Induced Constipation Sales by Type (2020-2025)
- 5.3 Americas Opioid-Induced Constipation Sales by Application (2020-2025)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC Opioid-Induced Constipation Sales by Region
 - 6.1.1 APAC Opioid-Induced Constipation Sales by Region (2020-2025)
 - 6.1.2 APAC Opioid-Induced Constipation Revenue by Region (2020-2025)
- 6.2 APAC Opioid-Induced Constipation Sales by Type (2020-2025)
- 6.3 APAC Opioid-Induced Constipation Sales by Application (2020-2025)
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

- 7.1 Europe Opioid-Induced Constipation by Country
 - 7.1.1 Europe Opioid-Induced Constipation Sales by Country (2020-2025)
 - 7.1.2 Europe Opioid-Induced Constipation Revenue by Country (2020-2025)
- 7.2 Europe Opioid-Induced Constipation Sales by Type (2020-2025)
- 7.3 Europe Opioid-Induced Constipation Sales by Application (2020-2025)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Opioid-Induced Constipation by Country

8.1.1 Middle East & Africa Opioid-Induced Constipation Sales by Country (2020-2025)

8.1.2 Middle East & Africa Opioid-Induced Constipation Revenue by Country
(2020-2025)

8.2 Middle East & Africa Opioid-Induced Constipation Sales by Type (2020-2025)

8.3 Middle East & Africa Opioid-Induced Constipation Sales by Application (2020-2025)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Opioid-Induced Constipation

10.3 Manufacturing Process Analysis of Opioid-Induced Constipation

10.4 Industry Chain Structure of Opioid-Induced Constipation

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Opioid-Induced Constipation Distributors

11.3 Opioid-Induced Constipation Customer

12 WORLD FORECAST REVIEW FOR OPIOID-INDUCED CONSTIPATION BY GEOGRAPHIC REGION

12.1 Global Opioid-Induced Constipation Market Size Forecast by Region

12.1.1 Global Opioid-Induced Constipation Forecast by Region (2026-2031)

12.1.2 Global Opioid-Induced Constipation Annual Revenue Forecast by Region (2026-2031)

12.2 Americas Forecast by Country (2026-2031)

12.3 APAC Forecast by Region (2026-2031)

12.4 Europe Forecast by Country (2026-2031)

12.5 Middle East & Africa Forecast by Country (2026-2031)

12.6 Global Opioid-Induced Constipation Forecast by Type (2026-2031)

12.7 Global Opioid-Induced Constipation Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 Takeda Pharmaceuticals

13.1.1 Takeda Pharmaceuticals Company Information

13.1.2 Takeda Pharmaceuticals Opioid-Induced Constipation Product Portfolios and Specifications

13.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)

13.1.4 Takeda Pharmaceuticals Main Business Overview

13.1.5 Takeda Pharmaceuticals Latest Developments

13.2 Bayer

13.2.1 Bayer Company Information

13.2.2 Bayer Opioid-Induced Constipation Product Portfolios and Specifications

13.2.3 Bayer Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)

13.2.4 Bayer Main Business Overview

13.2.5 Bayer Latest Developments

13.3 Sanofi

13.3.1 Sanofi Company Information

13.3.2 Sanofi Opioid-Induced Constipation Product Portfolios and Specifications

13.3.3 Sanofi Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)

13.3.4 Sanofi Main Business Overview

- 13.3.5 Sanofi Latest Developments
- 13.4 Mallinckrodt
 - 13.4.1 Mallinckrodt Company Information
 - 13.4.2 Mallinckrodt Opioid-Induced Constipation Product Portfolios and Specifications
 - 13.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.4.4 Mallinckrodt Main Business Overview
 - 13.4.5 Mallinckrodt Latest Developments
- 13.5 Salix (Bausch Health)
 - 13.5.1 Salix (Bausch Health) Company Information
 - 13.5.2 Salix (Bausch Health) Opioid-Induced Constipation Product Portfolios and Specifications
 - 13.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.5.4 Salix (Bausch Health) Main Business Overview
 - 13.5.5 Salix (Bausch Health) Latest Developments
- 13.6 AstraZeneca
 - 13.6.1 AstraZeneca Company Information
 - 13.6.2 AstraZeneca Opioid-Induced Constipation Product Portfolios and Specifications
 - 13.6.3 AstraZeneca Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.6.4 AstraZeneca Main Business Overview
 - 13.6.5 AstraZeneca Latest Developments
- 13.7 Progenics Pharmaceuticals
 - 13.7.1 Progenics Pharmaceuticals Company Information
 - 13.7.2 Progenics Pharmaceuticals Opioid-Induced Constipation Product Portfolios and Specifications
 - 13.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.7.4 Progenics Pharmaceuticals Main Business Overview
 - 13.7.5 Progenics Pharmaceuticals Latest Developments
- 13.8 Purdue Pharm
 - 13.8.1 Purdue Pharm Company Information
 - 13.8.2 Purdue Pharm Opioid-Induced Constipation Product Portfolios and Specifications
 - 13.8.3 Purdue Pharm Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.8.4 Purdue Pharm Main Business Overview
 - 13.8.5 Purdue Pharm Latest Developments

13.9 Nektar Therapeutics

13.9.1 Nektar Therapeutics Company Information

13.9.2 Nektar Therapeutics Opioid-Induced Constipation Product Portfolios and Specifications

13.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)

13.9.4 Nektar Therapeutics Main Business Overview

13.9.5 Nektar Therapeutics Latest Developments

13.10 Daiichi Sankyo

13.10.1 Daiichi Sankyo Company Information

13.10.2 Daiichi Sankyo Opioid-Induced Constipation Product Portfolios and Specifications

13.10.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)

13.10.4 Daiichi Sankyo Main Business Overview

13.10.5 Daiichi Sankyo Latest Developments

13.11 Prestige

13.11.1 Prestige Company Information

13.11.2 Prestige Opioid-Induced Constipation Product Portfolios and Specifications

13.11.3 Prestige Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)

13.11.4 Prestige Main Business Overview

13.11.5 Prestige Latest Developments

13.12 GSK

13.12.1 GSK Company Information

13.12.2 GSK Opioid-Induced Constipation Product Portfolios and Specifications

13.12.3 GSK Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)

13.12.4 GSK Main Business Overview

13.12.5 GSK Latest Developments

13.13 Shionogi

13.13.1 Shionogi Company Information

13.13.2 Shionogi Opioid-Induced Constipation Product Portfolios and Specifications

13.13.3 Shionogi Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)

13.13.4 Shionogi Main Business Overview

13.13.5 Shionogi Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

LIST OF TABLES

Table 1. Opioid-Induced Constipation Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & (\$ millions)

Table 2. Opioid-Induced Constipation Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & (\$ millions)

Table 3. Major Players of Methylnaltrexone Bromide

Table 4. Major Players of Lubiprostone

Table 5. Major Players of Naloxegol

Table 6. Major Players of Others

Table 7. Global Opioid-Induced Constipation Sales byType (2020-2025) & (K Units)

Table 8. Global Opioid-Induced Constipation Sales Market Share byType (2020-2025)

Table 9. Global Opioid-Induced Constipation Revenue byType (2020-2025) & (\$ million)

Table 10. Global Opioid-Induced Constipation Revenue Market Share byType (2020-2025)

Table 11. Global Opioid-Induced Constipation Sale Price byType (2020-2025) & (USD/Unit)

Table 12. Global Opioid-Induced Constipation Sale by Application (2020-2025) & (K Units)

Table 13. Global Opioid-Induced Constipation Sale Market Share by Application (2020-2025)

Table 14. Global Opioid-Induced Constipation Revenue by Application (2020-2025) & (\$ million)

Table 15. Global Opioid-Induced Constipation Revenue Market Share by Application (2020-2025)

Table 16. Global Opioid-Induced Constipation Sale Price by Application (2020-2025) & (USD/Unit)

Table 17. Global Opioid-Induced Constipation Sales by Company (2020-2025) & (K Units)

Table 18. Global Opioid-Induced Constipation Sales Market Share by Company (2020-2025)

Table 19. Global Opioid-Induced Constipation Revenue by Company (2020-2025) & (\$ millions)

Table 20. Global Opioid-Induced Constipation Revenue Market Share by Company (2020-2025)

Table 21. Global Opioid-Induced Constipation Sale Price by Company (2020-2025) & (USD/Unit)

Table 22. Key Manufacturers Opioid-Induced Constipation Producing Area Distribution and Sales Area

Table 23. Players Opioid-Induced Constipation Products Offered

Table 24. Opioid-Induced Constipation Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)

Table 25. New Products and Potential Entrants

Table 26. Market M&A Activity & Strategy

Table 27. Global Opioid-Induced Constipation Sales by Geographic Region (2020-2025) & (K Units)

Table 28. Global Opioid-Induced Constipation Sales Market Share Geographic Region (2020-2025)

Table 29. Global Opioid-Induced Constipation Revenue by Geographic Region (2020-2025) & (\$ millions)

Table 30. Global Opioid-Induced Constipation Revenue Market Share by Geographic Region (2020-2025)

Table 31. Global Opioid-Induced Constipation Sales by Country/Region (2020-2025) & (K Units)

Table 32. Global Opioid-Induced Constipation Sales Market Share by Country/Region (2020-2025)

Table 33. Global Opioid-Induced Constipation Revenue by Country/Region (2020-2025) & (\$ millions)

Table 34. Global Opioid-Induced Constipation Revenue Market Share by Country/Region (2020-2025)

Table 35. Americas Opioid-Induced Constipation Sales by Country (2020-2025) & (K Units)

Table 36. Americas Opioid-Induced Constipation Sales Market Share by Country (2020-2025)

Table 37. Americas Opioid-Induced Constipation Revenue by Country (2020-2025) & (\$ millions)

Table 38. Americas Opioid-Induced Constipation Sales byType (2020-2025) & (K Units)

Table 39. Americas Opioid-Induced Constipation Sales by Application (2020-2025) & (K Units)

Table 40. APAC Opioid-Induced Constipation Sales by Region (2020-2025) & (K Units)

Table 41. APAC Opioid-Induced Constipation Sales Market Share by Region (2020-2025)

Table 42. APAC Opioid-Induced Constipation Revenue by Region (2020-2025) & (\$ millions)

Table 43. APAC Opioid-Induced Constipation Sales byType (2020-2025) & (K Units)

Table 44. APAC Opioid-Induced Constipation Sales by Application (2020-2025) & (K

Units)

Table 45. Europe Opioid-Induced Constipation Sales by Country (2020-2025) & (K Units)

Table 46. Europe Opioid-Induced Constipation Revenue by Country (2020-2025) & (\$ millions)

Table 47. Europe Opioid-Induced Constipation Sales byType (2020-2025) & (K Units)

Table 48. Europe Opioid-Induced Constipation Sales by Application (2020-2025) & (K Units)

Table 49. Middle East & Africa Opioid-Induced Constipation Sales by Country (2020-2025) & (K Units)

Table 50. Middle East & Africa Opioid-Induced Constipation Revenue Market Share by Country (2020-2025)

Table 51. Middle East & Africa Opioid-Induced Constipation Sales byType (2020-2025) & (K Units)

Table 52. Middle East & Africa Opioid-Induced Constipation Sales by Application (2020-2025) & (K Units)

Table 53. Key Market Drivers & Growth Opportunities of Opioid-Induced Constipation

Table 54. Key Market Challenges & Risks of Opioid-Induced Constipation

Table 55. Key IndustryTrends of Opioid-Induced Constipation

Table 56. Opioid-Induced Constipation Raw Material

Table 57. Key Suppliers of Raw Materials

Table 58. Opioid-Induced Constipation Distributors List

Table 59. Opioid-Induced Constipation Customer List

Table 60. Global Opioid-Induced Constipation SalesForecast by Region (2026-2031) & (K Units)

Table 61. Global Opioid-Induced Constipation RevenueForecast by Region (2026-2031) & (\$ millions)

Table 62. Americas Opioid-Induced Constipation SalesForecast by Country (2026-2031) & (K Units)

Table 63. Americas Opioid-Induced Constipation Annual RevenueForecast by Country (2026-2031) & (\$ millions)

Table 64. APAC Opioid-Induced Constipation SalesForecast by Region (2026-2031) & (K Units)

Table 65. APAC Opioid-Induced Constipation Annual RevenueForecast by Region (2026-2031) & (\$ millions)

Table 66. Europe Opioid-Induced Constipation SalesForecast by Country (2026-2031) & (K Units)

Table 67. Europe Opioid-Induced Constipation RevenueForecast by Country (2026-2031) & (\$ millions)

Table 68. Middle East & Africa Opioid-Induced Constipation SalesForecast by Country (2026-2031) & (K Units)

Table 69. Middle East & Africa Opioid-Induced Constipation RevenueForecast by Country (2026-2031) & (\$ millions)

Table 70. Global Opioid-Induced Constipation SalesForecast byType (2026-2031) & (K Units)

Table 71. Global Opioid-Induced Constipation RevenueForecast byType (2026-2031) & (\$ millions)

Table 72. Global Opioid-Induced Constipation SalesForecast by Application (2026-2031) & (K Units)

Table 73. Global Opioid-Induced Constipation RevenueForecast by Application (2026-2031) & (\$ millions)

Table 74.Takeda Pharmaceuticals Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors

Table 75.Takeda Pharmaceuticals Opioid-Induced Constipation Product Portfolios and Specifications

Table 76.Takeda Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 77.Takeda Pharmaceuticals Main Business

Table 78.Takeda Pharmaceuticals Latest Developments

Table 79. Bayer Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors

Table 80. Bayer Opioid-Induced Constipation Product Portfolios and Specifications

Table 81. Bayer Opioid-Induced Constipation Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 82. Bayer Main Business

Table 83. Bayer Latest Developments

Table 84. Sanofi Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors

Table 85. Sanofi Opioid-Induced Constipation Product Portfolios and Specifications

Table 86. Sanofi Opioid-Induced Constipation Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 87. Sanofi Main Business

Table 88. Sanofi Latest Developments

Table 89. Mallinckrodt Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors

Table 90. Mallinckrodt Opioid-Induced Constipation Product Portfolios and Specifications

Table 91. Mallinckrodt Opioid-Induced Constipation Sales (K Units), Revenue (\$

Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 92. Mallinckrodt Main Business

Table 93. Mallinckrodt Latest Developments

Table 94. Salix (Bausch Health) Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors

Table 95. Salix (Bausch Health) Opioid-Induced Constipation Product Portfolios and Specifications

Table 96. Salix (Bausch Health) Opioid-Induced Constipation Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 97. Salix (Bausch Health) Main Business

Table 98. Salix (Bausch Health) Latest Developments

Table 99. AstraZeneca Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors

Table 100. AstraZeneca Opioid-Induced Constipation Product Portfolios and Specifications

Table 101. AstraZeneca Opioid-Induced Constipation Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 102. AstraZeneca Main Business

Table 103. AstraZeneca Latest Developments

Table 104. Progenics Pharmaceuticals Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors

Table 105. Progenics Pharmaceuticals Opioid-Induced Constipation Product Portfolios and Specifications

Table 106. Progenics Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 107. Progenics Pharmaceuticals Main Business

Table 108. Progenics Pharmaceuticals Latest Developments

Table 109. Purdue Pharm Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors

Table 110. Purdue Pharm Opioid-Induced Constipation Product Portfolios and Specifications

Table 111. Purdue Pharm Opioid-Induced Constipation Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 112. Purdue Pharm Main Business

Table 113. Purdue Pharm Latest Developments

Table 114. NektarTherapeutics Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors

Table 115. NektarTherapeutics Opioid-Induced Constipation Product Portfolios and Specifications

Table 116. NektarTherapeutics Opioid-Induced Constipation Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 117. NektarTherapeutics Main Business

Table 118. NektarTherapeutics Latest Developments

Table 119. Daiichi Sankyo Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors

Table 120. Daiichi Sankyo Opioid-Induced Constipation Product Portfolios and Specifications

Table 121. Daiichi Sankyo Opioid-Induced Constipation Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 122. Daiichi Sankyo Main Business

Table 123. Daiichi Sankyo Latest Developments

Table 124. Prestige Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors

Table 125. Prestige Opioid-Induced Constipation Product Portfolios and Specifications

Table 126. Prestige Opioid-Induced Constipation Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 127. Prestige Main Business

Table 128. Prestige Latest Developments

Table 129. GSK Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors

Table 130. GSK Opioid-Induced Constipation Product Portfolios and Specifications

Table 131. GSK Opioid-Induced Constipation Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 132. GSK Main Business

Table 133. GSK Latest Developments

Table 134. Shionogi Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors

Table 135. Shionogi Opioid-Induced Constipation Product Portfolios and Specifications

Table 136. Shionogi Opioid-Induced Constipation Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 137. Shionogi Main Business

Table 138. Shionogi Latest Developments

LIST OFFIGURES

Figure 1. Picture of Opioid-Induced Constipation

- Figure 2. Opioid-Induced Constipation Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Opioid-Induced Constipation Sales Growth Rate 2020-2031 (K Units)
- Figure 7. Global Opioid-Induced Constipation Revenue Growth Rate 2020-2031 (\$ millions)
- Figure 8. Opioid-Induced Constipation Sales by Geographic Region (2020, 2024 & 2031) & (\$ millions)
- Figure 9. Opioid-Induced Constipation Sales Market Share by Country/Region (2024)
- Figure 10. Opioid-Induced Constipation Sales Market Share by Country/Region (2020, 2024 & 2031)
- Figure 11. Product Picture of Methylbuprenorphine Hydrochloride
- Figure 12. Product Picture of Lubiprostone
- Figure 13. Product Picture of Naloxegol
- Figure 14. Product Picture of Others
- Figure 15. Global Opioid-Induced Constipation Sales Market Share byType in 2025
- Figure 16. Global Opioid-Induced Constipation Revenue Market Share byType (2020-2025)
- Figure 17. Opioid-Induced Constipation Consumed in Hospital
- Figure 18. Global Opioid-Induced Constipation Market: Hospital (2020-2025) & (K Units)
- Figure 19. Opioid-Induced Constipation Consumed in Pharmacy
- Figure 20. Global Opioid-Induced Constipation Market: Pharmacy (2020-2025) & (K Units)
- Figure 21. Opioid-Induced Constipation Consumed in Other
- Figure 22. Global Opioid-Induced Constipation Market: Other (2020-2025) & (K Units)
- Figure 23. Global Opioid-Induced Constipation Sale Market Share by Application (2024)
- Figure 24. Global Opioid-Induced Constipation Revenue Market Share by Application in 2025
- Figure 25. Opioid-Induced Constipation Sales by Company in 2025 (K Units)
- Figure 26. Global Opioid-Induced Constipation Sales Market Share by Company in 2025
- Figure 27. Opioid-Induced Constipation Revenue by Company in 2025 (\$ millions)
- Figure 28. Global Opioid-Induced Constipation Revenue Market Share by Company in 2025
- Figure 29. Global Opioid-Induced Constipation Sales Market Share by Geographic Region (2020-2025)
- Figure 30. Global Opioid-Induced Constipation Revenue Market Share by Geographic Region in 2025

- Figure 31. Americas Opioid-Induced Constipation Sales 2020-2025 (K Units)
- Figure 32. Americas Opioid-Induced Constipation Revenue 2020-2025 (\$ millions)
- Figure 33. APAC Opioid-Induced Constipation Sales 2020-2025 (K Units)
- Figure 34. APAC Opioid-Induced Constipation Revenue 2020-2025 (\$ millions)
- Figure 35. Europe Opioid-Induced Constipation Sales 2020-2025 (K Units)
- Figure 36. Europe Opioid-Induced Constipation Revenue 2020-2025 (\$ millions)
- Figure 37. Middle East & Africa Opioid-Induced Constipation Sales 2020-2025 (K Units)
- Figure 38. Middle East & Africa Opioid-Induced Constipation Revenue 2020-2025 (\$ millions)
- Figure 39. Americas Opioid-Induced Constipation Sales Market Share by Country in 2025
- Figure 40. Americas Opioid-Induced Constipation Revenue Market Share by Country (2020-2025)
- Figure 41. Americas Opioid-Induced Constipation Sales Market Share byType (2020-2025)
- Figure 42. Americas Opioid-Induced Constipation Sales Market Share by Application (2020-2025)
- Figure 43. United States Opioid-Induced Constipation Revenue Growth 2020-2025 (\$ millions)
- Figure 44. Canada Opioid-Induced Constipation Revenue Growth 2020-2025 (\$ millions)
- Figure 45. Mexico Opioid-Induced Constipation Revenue Growth 2020-2025 (\$ millions)
- Figure 46. Brazil Opioid-Induced Constipation Revenue Growth 2020-2025 (\$ millions)
- Figure 47. APAC Opioid-Induced Constipation Sales Market Share by Region in 2025
- Figure 48. APAC Opioid-Induced Constipation Revenue Market Share by Region (2020-2025)
- Figure 49. APAC Opioid-Induced Constipation Sales Market Share byType (2020-2025)
- Figure 50. APAC Opioid-Induced Constipation Sales Market Share by Application (2020-2025)
- Figure 51. China Opioid-Induced Constipation Revenue Growth 2020-2025 (\$ millions)
- Figure 52. Japan Opioid-Induced Constipation Revenue Growth 2020-2025 (\$ millions)
- Figure 53. South Korea Opioid-Induced Constipation Revenue Growth 2020-2025 (\$ millions)
- Figure 54. Southeast Asia Opioid-Induced Constipation Revenue Growth 2020-2025 (\$ millions)
- Figure 55. India Opioid-Induced Constipation Revenue Growth 2020-2025 (\$ millions)
- Figure 56. Australia Opioid-Induced Constipation Revenue Growth 2020-2025 (\$ millions)
- Figure 57. ChinaTaiwan Opioid-Induced Constipation Revenue Growth 2020-2025 (\$

millions)

Figure 58. Europe Opioid-Induced Constipation Sales Market Share by Country in 2025

Figure 59. Europe Opioid-Induced Constipation Revenue Market Share by Country (2020-2025)

Figure 60. Europe Opioid-Induced Constipation Sales Market Share byType (2020-2025)

Figure 61. Europe Opioid-Induced Constipation Sales Market Share by Application (2020-2025)

Figure 62. Germany Opioid-Induced Constipation Revenue Growth 2020-2025 (\$ millions)

Figure 63. France Opioid-Induced Constipation Revenue Growth 2020-2025 (\$ millions)

Figure 64. UK Opioid-Induced Constipation Revenue Growth 2020-2025 (\$ millions)

Figure 65. Italy Opioid-Induced Constipation Revenue Growth 2020-2025 (\$ millions)

Figure 66. Russia Opioid-Induced Constipation Revenue Growth 2020-2025 (\$ millions)

Figure 67. Middle East & Africa Opioid-Induced Constipation Sales Market Share by Country (2020-2025)

Figure 68. Middle East & Africa Opioid-Induced Constipation Sales Market Share byType (2020-2025)

Figure 69. Middle East & Africa Opioid-Induced Constipation Sales Market Share by Application (2020-2025)

Figure 70. Egypt Opioid-Induced Constipation Revenue Growth 2020-2025 (\$ millions)

Figure 71. South Africa Opioid-Induced Constipation Revenue Growth 2020-2025 (\$ millions)

Figure 72. Israel Opioid-Induced Constipation Revenue Growth 2020-2025 (\$ millions)

Figure 73. Turkey Opioid-Induced Constipation Revenue Growth 2020-2025 (\$ millions)

Figure 74. GCC Countries Opioid-Induced Constipation Revenue Growth 2020-2025 (\$ millions)

Figure 75. Manufacturing Cost Structure Analysis of Opioid-Induced Constipation in 2025

Figure 76. Manufacturing Process Analysis of Opioid-Induced Constipation

Figure 77. Industry Chain Structure of Opioid-Induced Constipation

Figure 78. Channels of Distribution

Figure 79. Global Opioid-Induced Constipation Sales MarketForecast by Region (2026-2031)

Figure 80. Global Opioid-Induced Constipation Revenue Market ShareForecast by Region (2026-2031)

Figure 81. Global Opioid-Induced Constipation Sales Market ShareForecast byType (2026-2031)

Figure 82. Global Opioid-Induced Constipation Revenue Market ShareForecast byType

(2026-2031)

Figure 83. Global Opioid-Induced Constipation Sales Market ShareForecast by Application (2026-2031)

Figure 84. Global Opioid-Induced Constipation Revenue Market ShareForecast by Application (2026-2031)

I would like to order

Product name: Global Opioid-Induced Constipation Market Growth 2025-2031

Product link: <https://marketpublishers.com/r/G575CB7820FEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G575CB7820FEN.html>